melatonin + cannabinoid

Melatonin + cannabinoid is a microencapsulated combination drug candidate being developed by APIRx Pharma Sciences for the treatment of sleep disorders. The formulation utilizes microencapsulation technology to deliver melatonin, a hormone that regulates circadian rhythms, alongside a cannabinoid to engage the endocannabinoid system. By targeting both melatonin receptors (MT1 and MT2) and cannabinoid receptors (CB1 and CB2), the therapy aims to provide a synergistic effect on sleep regulation and maintenance. It is currently in the preclinical stage of development, with the microencapsulation intended to optimize the release profile and bioavailability of the active ingredients.

Other names

microencapsulated melatonin + cannabinoidmelatonin + cannabinoid microencapsulation